12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AzaSite Plus: Completed Phase III enrollment

InSite completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 days. InSite has an SPA from FDA for DOUBle.

AzaSite Plus has completed...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >